Of the total patients (n=120), 80 (66%) had anti-NMDAR antibodies in serum/CSF and were classified as ANMDARE; 6 of them (7.5%) showed PE (5 females; median age: 18.5 years, IQR: 28.5 years). MRIs were performed between 5 days and 4 months after the clinical onset. All MRIs were done after lumbar puncture (LP) (median days after LP: 3.5 [IQR: 6] days). No symptom or other imaging feature suggested intracranial hypotension. Their median CSF cell count, glucose and protein levels were 6.5 (IQR: 44.5), 68±14.8 mg/dL, and 31.5 (IQR: 319.25) mg/dL, respectively. CSF PCR panel was available in four cases and tested positive in two (EBV and CMV). In four patients the enhancement was predominantly pachymeningeal and more prominent in the convexity and over the parietal and occipital lobes. All patients received immunomodulatory therapy and, those who tested positive for virus, also acyclovir. One patient died after a protracted hospital stay; her CSF PCR panel tested negative.